Recently Published Independent Research Study Detects Gene Variation In Non-Small Cell Lung Cancer Using The Sequenom Massarray® Research Use System

SAN DIEGO, May 29, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported on a recently released publication in which the Sequenom MassARRAY® System (for research use only) was used in a groundbreaking independent study that detected the transforming fusion gene EML4/ ALK in non-small cell lung cancer. The study was conducted by researchers at Kinki University in Japan and appears in the May online issue of The Journal of Thoracic Oncology. The full results of the study can be found online at: http://journals.lww.com/jto/Abstract/2012/05000/A_Novel_Mass_Spectrometry_Based_Assay_for.20.aspx. 

The research study describes an assay which detects the transforming fusion gene echinoderm microtubule-associated protein-like 4 ( EML4) anaplastic lymphoma kinase ( ALK) in non-small cell lung cancer (NSCLC). Current research methods have limitations in terms of detecting different variants, and this study demonstrates the successful detection of nine EML4-ALK variants in total RNA obtained from formalin-fixed, paraffin-embedded (FFPE) specimens of NSCLC tissue.

As stated in the paper, "Our assay is able to distinguish between the different EML4-ALK variants in a small amount of formalin-fixed, paraffin embedded NSCLC tissue and it should prove to be a useful tool for the detection of EML4-ALK variants in testing for this fusion gene," said Kazuto Nishio, MD, Ph.D., Lead Author, Kinki University.

The EML4-ALK translocation occurs in five to 10 percent of lung cancer patients. Crizotinib, a tyrosine kinase activity inhibitor of ALK and MET, has been shown to be effective for the treatment of lung cancer patients harboring this translocation. In contrast to dual-color split-signal FISH analysis that is commonly used for screening ALK rearrangement or real-time PCR assays, this assay, utilizing the MassARRAY System, can detect nine EML4-ALK variants and wild-type ALK including 1, 2, 3a, 3b, 4, 5a, 5b, 6, and 7 transcripts.  

1 2 Next › Last »